164 related articles for article (PubMed ID: 35342129)
1. Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib.
Nakashima S; Sekine A; Sawa N; Kawamura Y; Kono K; Kinowaki K; Kawada M; Hasegawa E; Akuta N; Suzuki Y; Ohashi K; Takaichi K; Ubara Y; Hoshino J
Intern Med; 2022 Oct; 61(20):3083-3088. PubMed ID: 35342129
[TBL] [Abstract][Full Text] [Related]
2. Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma.
Hyogo Y; Kiyota N; Otsuki N; Goto S; Imamura Y; Chayahara N; Toyoda M; Nibu KI; Hyodo T; Hara S; Masuoka H; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Case Rep Oncol; 2018; 11(3):735-741. PubMed ID: 30519176
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.
Kato T; Mizuno R; Miyake H
Int J Urol; 2024 May; 31(5):465-474. PubMed ID: 38318663
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib-related renal microangiopathy: a case series.
Delsante M; Monroy-Trujillo JM; Carter-Monroe N; Ball DW; Rosenberg AZ
Virchows Arch; 2022 Feb; 480(2):467-473. PubMed ID: 33959820
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib-induced glomerular microangiopathy: a case report.
Hasegawa M; Uehara A; Suzuki T; Sekine R; Yazawa M; Ichikawa D; Koike J; Shibagaki Y
CEN Case Rep; 2020 Nov; 9(4):295-300. PubMed ID: 32279192
[TBL] [Abstract][Full Text] [Related]
8. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report.
Furuto Y; Hashimoto H; Namikawa A; Outi H; Takahashi H; Horiuti H; Honda K; Shibuya Y
BMC Nephrol; 2018 Oct; 19(1):273. PubMed ID: 30340546
[TBL] [Abstract][Full Text] [Related]
9. Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
Masaki C; Sugino K; Kobayashi S; Hosoi Y; Ono R; Yamazaki H; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
BMC Cancer; 2021 Aug; 21(1):894. PubMed ID: 34353305
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M
Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers.
Suyama K; Iwase H
Cancer Control; 2018; 25(1):1073274818789361. PubMed ID: 30032643
[TBL] [Abstract][Full Text] [Related]
13. Proteinuria reduction with SGLT2 inhibitors in a patient treated with tyrosine kinase inhibitor lenvatinib.
Fages V; Jannin A; Maanaoui M; Glowacki F; Do Cao C
J Nephrol; 2024 Jan; 37(1):187-189. PubMed ID: 37418091
[TBL] [Abstract][Full Text] [Related]
14. Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma.
Sasaki R; Fukushima M; Haraguchi M; Honda T; Miuma S; Miyaaki H; Nakao K
Medicine (Baltimore); 2022 May; 101(19):e29289. PubMed ID: 35583540
[TBL] [Abstract][Full Text] [Related]
15. Pneumothorax during lenvatinib treatment for hepatocellular carcinoma with lung metastasis.
Kawanishi Y; Kuwahara M; Utsunomiya M; Ishida N; Ishikawa Y; Hiroi M; Akimori T
Clin J Gastroenterol; 2021 Feb; 14(1):288-292. PubMed ID: 33108567
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literatures.
Yin Q; Guo N; Zhou X; Xu H; Lei S; Fu P; Zhong H
BMC Nephrol; 2022 Mar; 23(1):112. PubMed ID: 35305559
[TBL] [Abstract][Full Text] [Related]
17. The action and resistance mechanisms of Lenvatinib in liver cancer.
Buttell A; Qiu W
Mol Carcinog; 2023 Dec; 62(12):1918-1934. PubMed ID: 37671815
[TBL] [Abstract][Full Text] [Related]
18. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
19. Late renal toxicity in patient with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib: A case report and literature review.
Pham B; Kwon SM; Castillo DR; Majeed Y; Ahmad S; Hou J; Ganesan L; Mohammad S; Cao H
J Oncol Pharm Pract; 2022 Dec; 28(8):1930-1935. PubMed ID: 35369811
[TBL] [Abstract][Full Text] [Related]
20. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
